AbbVie

News

EU first to clear AbbVie's Rinvoq for alopecia areata

AbbVie's fast-growing JAK inhibitor Rinvoq has been cleared for alopecia areata in the EU, its first market for the hair loss disorder.

News

Drugmakers asked to defend Chinese trials; reports

The House China Select Committee has quizzed MSD, AbbVie, Bristol Myers Squibb, and Pfizer about the ethics of clinical trials run in China.

News

AbbVie climbs post-Allergan M&A peak with Apogee buy

AbbVie has announced its biggest acquisition since the $63 billion merger with Allergan, buying Apogee and its 'mega-blockbuster' immunology pipeline.

Oncology

ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o...

For years, ADCs have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether?

News

AbbVie's migraine drug cleared for migraine attacks on NHS

AbbVie's Aquipta can now be commissioned by the NHS in England and Wales as an acute treatment for migraine, after a NICE decision.

News

AbbVie's ovarian cancer drug Elahere gets NHS green light

AbbVie's Elahere has become the first new NHS therapy in more than 20 years for resistant ovarian cancer, providing an alternative to chemotherapy.

EU first to clear AbbVie's Rinvoq for alopecia areata

Drugmakers asked to defend Chinese trials; reports

AbbVie climbs post-Allergan M&A peak with Apogee buy

ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o...

AbbVie's migraine drug cleared for migraine attacks on NHS

AbbVie's ovarian cancer drug Elahere gets NHS green light

TransThera's resistant biliary cancer drug cleared in China

Discover a new era of healthcare panel engagement: Grounded ...

AbbVie

Editor's Picks